​

Barinthus Biotherapeutics Stock (NASDAQ:BRNS)

ForecastFinancialsChart

Previous Close

$0.76

52W Range

$0.51 - $1.83

50D Avg

$0.63

200D Avg

$0.66

Market Cap

$30.23M

Avg Vol (3M)

$51.76K

Beta

-0.36

Div Yield

-

BRNS Company Profile

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

14

IPO Date

Apr 30, 2021

Website

BRNS Performance

BRNS Financial Summary

Dec 25Dec 24Dec 23
Revenue-$14.97M$802.00K
Operating Income$506.00K$-67.97M$-83.91M
Net Income$-66.43M$-61.07M$-73.35M
EBITDA$506.00K$-55.37M$-71.06M
Basic EPS$-1.64$-1.55$-1.91
Diluted EPS$-1.64$-1.55$-1.91

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
OKUROnKure Therapeutics, Inc.
MDCXMedicus Pharma Ltd. Common Stock
TPSTTempest Therapeutics, Inc.
ALGSAligos Therapeutics, Inc.
KPTIKaryopharm Therapeutics Inc.
INMBINmune Bio, Inc.
SNTISenti Biosciences, Inc.
MRSNMersana Therapeutics, Inc.